QUOTED. March 08, 2019. Ifeanyi Onyeacholem.
Executive Summary
The market for breast cancer imaging, biopsy and tissue-sparing treatment products is expected to reach $5.8bn in 2022, a CAGR of 5.9% from 2017. Many radiologists believe that digital breast tomosynthesis will become the gold standard. See what Kaiser Permanente's radiologist Ifeanyi Onyeacholem said about it here.
"It clears up a lot of questions a 2D mammogram cannot necessarily clear up. The technology uses X-rays, but instead of a mammogram that's in 2D, it is putting a 3D object into a 3D image and creates slices through the breast that is similar to a CT scan – so on each level it helps us decide if it's regular tissue or more than that." –Ifeanyi Onyeacholem, radiologist, Kaiser Permanente, San Diego
Click here for a free trial of Medtech Insight